FDA recalls NAD+ pharmaceutical powder vials due to sterility concerns
Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide powder vials nationwide due to lack of assurance of sterility. The recall affects 8,982 vials distributed across the USA, Puerto Rico, and US Virgin Islands.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard (lack of sterility assurance) is theoretical without confirmed contamination or adverse health effects, meeting the criterion for High severity: risk-of-harm products where injury has not yet been reported.
Plain-English summary
Olympia Compounding Pharmacy dba Olympia Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide lyophilized powder for reconstitution. The recalled product is supplied in multi-dose 500 mg vials marked as Rx Only. A total of 8,982 vials have been distributed.
The recall was initiated due to lack of assurance of sterility. Sterility is critical for injectable pharmaceutical preparations. The affected lots are: A2401422 (BUD 1/14/2023), K41001 (BUD 11/1/2022), K41130 (BUD 11/30/2022), L24113 (BUD 12/13/2022), and L41102 (BUD 12/2/2022).
The product was distributed nationwide in the USA, Puerto Rico, and US Virgin Islands. Healthcare providers and patients who have received this product should cease use and contact their pharmacy or healthcare provider for guidance. Do not use any remaining doses from affected lots.
The recalled product
- Product
- NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155 Orlando, FL 32835. NDC 73198-0083-00.
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Compounded Injectable
- Hazard
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lots: A2401422 BUD: 1/14/2023
- K41001 BUD: 11/1/2022
- K41130 BUD: 11/30/2022
- L24113 BUD: 12/13/2022
- L41102 BUD: 12/2/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27